Literature DB >> 20417092

Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study.

Jacqueline Duffour1, Simon Thézenas, Olivier Dereure, Agnès Garcin, Julie Caron, Emmanuelle Samalin, Fabienne Portales, Catherine Fiess, Patrick Chalbos, Christine Gestin-Boyer, Marc Ychou, Bernard Guillot.   

Abstract

The aim of this study was to measure the inter-observer agreement between two teams of three dermatologists and oncologists in labelling and grading the cetuximab-induced dermatological toxicities from 98 photographs performed in a cohort of 15 patients with metastatic colorectal cancer receiving cetuximab-based chemotherapy. Kappa coefficient (κ) assessed inter-observer grading agreement. Both teams defined by the same terms eight of the 13 (62%) toxic effects reported together. Discrepancies concerned the labelling of rash desquamation, hand-foot syndrome and xerosis and the grading (different and often going in the opposite direction) of various toxicities such as paronychia, xerosis, desquamation and hand-foot syndrome (κ value less than 0.40). Acneiform eruption was recognised by both teams, but the grading allocated by oncologists was lower. Our results suggested the need for a real consensus between oncologists and dermatologists for labelling and grading these dermatological toxicities. Better training of oncologists by using a dermatological atlas would improve inter-observer agreement.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20417092     DOI: 10.1016/j.ejca.2010.03.008

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

1.  Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.

Authors:  Carmine Pinto; Carlo Antonio Barone; Giampiero Girolomoni; Elvio Grazioso Russi; Marco Carlo Merlano; Daris Ferrari; Evaristo Maiello
Journal:  Oncologist       Date:  2011-01-27

2.  Skin rash during cetuximab treatment in advanced colorectal cancer: is age a clinical predictor?

Authors:  Jacopo Giuliani; Marina Marzola
Journal:  J Gastrointest Cancer       Date:  2013-06

3.  Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study.

Authors:  Sacha I Rothschild; Daniel Betticher; Reinhard Zenhäusern; Sandro Anchisi; Roger von Moos; Miklos Pless; Peter Moosmann; Razvan A Popescu; Antonello Calderoni; Marco Dressler; Daniel Rauch; Stefanie Pederiva; Regina Woelky; Claudia Papet; Vera Bühler; Markus Borner
Journal:  Cancer Chemother Pharmacol       Date:  2019-08-23       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.